王红阳

王红阳

2022-09-18来源:临床医学院



19521月生,主任医师,长江特聘教授,博导,肿瘤学、分子生物学专家,中国工程院院士,发展中国家科学院院士。现任国家肝癌科学中心主任、国际合作生物信号转导研究中心主任。兼任中国女科技工作者协会会长,中国抗癌协会副理事长等。是首届国家创新团队奖的带头人和全国创新争先奖奖章获得者。

一、学习及工作经历

  • 1981-02 – 1984-02: 硕士,第二军医大学

  • 1989-06 – 1992-09: 博士,德国乌尔姆大学

  • 1992-12 – 1995-11: 博士后,德国Max-Planck研究院生化所

  • 1995-12 – 1998-01: 课题组长,PI,高级研究人员,德国Max-Planck研究院生化所

  • 1997-01 – 至今: 主任,博导,教授,第二军医大学

二、学术成果及影响

长期从事肿瘤的基础与临床研究,对肿瘤的炎-癌转化、信号网络调控、肝癌早诊与诊断试剂研发等有重要建树。在CellCell MetabolismScience Translational MedicineCancer Cell等国际有影响的主流期刊发表SCI论文300篇,获发明专利授权31项(国际专利3项),主持研发的我国第一个具有完全知识产权的Glypican-3肝癌诊断试剂临床应用14万人次。以第一完成人获首届国家科技进步奖创新团队奖、国家自然科学二等奖等9项,获全国创新争先奖奖章、全国三八红旗手标兵等称号。先后主持国家和省部级重大、重点科技攻关项目十余项。

三、在研项目(仅限于主要负责人)

项目名称、来源、经费指标卡号

总经费(万元)

起止日期

肝脏微器官/类器官培养体系的建立、功能调控及其在重大疾病中的应用 国自然重点项目

296

2019-01-012023-12-31

基于重要靶点的肝癌多模态诊疗研究 国自然重大研究计划

310

2019-01-012022-12-31

常见恶性肿瘤网络调控与精准诊治研究 中科大实验室启动经费

1000

2018-12-012022-12-31

四、主要研究方向(招生专业)及内容

生物学

细胞生物学

1) 细胞信号转导;

2) 细胞外囊泡的功能和分子机制。


临床医学

肿瘤学

1) 炎症、代谢等促进肿瘤发生、发展的分子机制及其调控网络;

2) 肿瘤干细胞的信号调控;

3) 肿瘤的早期诊断、分子分型与个性化。

五、代表性论文(近五年)

1.Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He J, Ma W, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, Deng X, Ding W, Feng Y, Gan R, Guo C, Guo W, He S, Jiang C, Liang J, Li YM, Lin J, Ling Y, Liu H, Liu J, Liu N, Liu SQ, Luo M, Ma Q, Song Q, Sun W, Wang G, Wang F, Wang Y, Wen X, Wu Q, Xu G, Xie X, Xiong X, Xing X, Xu H, Yin C, Yu D, Yu K, Yuan J, Zhang B, Zhang P, Zhang T, Zhao J, Zhao P, Zhou J, Zhou W, Zhong S, Zhong X, Zhang S, Zhu L, Zhu P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P, Jiang Q, Huang Z, Bei JX, Wei L, Bian XW, Liu X, Cheng T, Li X, Wang FS, Wang H, Zhang Z, Qu K, Wang X, Chen J, Jin R. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 2021;184:1895-1913 e19.

2.Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D, Cui X, He Y, Xiang W, Han Q, Tang L, Yang W, Wang H. NAD(+) Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metab 2021;33:110-127 e5.

3.Jiang TY, Pan YF, Wan ZH, Lin YK, Zhu B, Yuan ZG, Ma YH, Shi YY, Zeng TM, Dong LW, Tan YX, Wang HY. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Sci Transl Med 2020;12.

4.Zheng B, Wang D, Qiu X, Luo G, Wu T, Yang S, Li Z, Zhu Y, Wang S, Wu R, Sui C, Gu Z, Shen S, Jeong S, Wu X, Gu J, Wang H, Chen L. Trajectory and Functional Analysis of PD-1(high) CD4(+)CD8(+) T Cells in Hepatocellular Carcinoma by Single-Cell Cytometry and Transcriptome Sequencing. Adv Sci (Weinh) 2020;7:2000224.

5.Chen L, Abou-Alfa GK, Zheng B, Liu JF, Bai J, Du LT, Qian YS, Fan R, Liu XL, Wu L, Hou JL, Wang HY. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res 2021;31:589-592.

6.Cheng Z, Liang X, Zhang C, Wang R, Wei T, Ning B, Poreba E, Li L, Wang H, Ding J. SOX9-transactived long non-coding RNA NEAT1 promotes the self-renewal of liver cancer stem cells through PKA/Hippo signaling. Signal Transduct Target Ther 2021;6:87.

7.Zheng Y, Liu X, Le W, Xie L, Li H, Wen W, Wang S, Ma S, Huang Z, Ye J, Shi W, Ye Y, Liu Z, Song M, Zhang W, Han JJ, Belmonte JCI, Xiao C, Qu J, Wang H, Liu GH, Su W. A human circulating immune cell landscape in aging and COVID-19. Protein Cell 2020;11:740-770.

8.Qin WH, Yang ZS, Li M, Chen Y, Zhao XF, Qin YY, Song JQ, Wang BB, Yuan B, Cui XL, Shen F, He J, Bi YF, Ning G, Fu J, Wang HY. High Serum Levels of Cholesterol Increase Antitumor Functions of Nature Killer Cells and Reduce Growth of Liver Tumors in Mice. Gastroenterology 2020;158:1713-1727.

9.Wan ZH, Jiang TY, Shi YY, Pan YF, Lin YK, Ma YH, Yang C, Feng XF, Huang LF, Kong XN, Ding ZW, Tan YX, Dong LW, Wang HY. RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding. Hepatology 2020;71:2005-2022.

10.Wei Y, Chen X, Liang C, Ling Y, Yang X, Ye X, Zhang H, Yang P, Cui X, Ren Y, Xin X, Li H, Wang R, Wang W, Jiang F, Liu S, Ding J, Zhang B, Li L, Wang H. A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma. Hepatology 2020;71:130-147.

11.Xiang DM, Sun W, Zhou T, Zhang C, Cheng Z, Li SC, Jiang W, Wang R, Fu G, Cui X, Hou G, Jin GZ, Li H, Hou C, Liu H, Wang H, Ding J. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut 2019;68:1858-1871.

12.Fu GB, Huang WJ, Zeng M, Zhou X, Wu HP, Liu CC, Wu H, Weng J, Zhang HD, Cai YC, Ashton C, Ding M, Tang D, Zhang BH, Gao Y, Yu WF, Zhai B, He ZY, Wang HY, Yan HX. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens. Cell Res 2019;29:8-22.

13.Liu J, Jiang J, Mo J, Liu D, Cao D, Wang H, He Y. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma. Hepatology 2019;69:196-208.

14.Cheng Z, He Z, Cai Y, Zhang C, Fu G, Li H, Sun W, Liu C, Cui X, Ning B, Xiang D, Zhou T, Li X, Xie W, Wang H, Ding J. Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors. Cell Res 2019;29:124-135.

15.Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, Shi G, Ge Y, Gao P, Yang Y, Ke A, Xiao L, Dong R, Zhu Y, Yang X, Wang J, Zhu T, Yang D, Huang X, Sui C, Qiu S, Shen F, Sun H, Zhou W, Zhou J, Nie J, Zeng C, Stroup EK, Chiu BC, Lau WY, He C, Wang H, Zhang W, Fan J. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut 2019;68:2195-2205.

16.Xiang DM, Sun W, Ning BF, Zhou TF, Li XF, Zhong W, Cheng Z, Xia MY, Wang X, Deng X, Wang W, Li HY, Cui XL, Li SC, Wu B, Xie WF, Wang HY, Ding J. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut 2018;67:1704-1715.

17.Ou-Yang Q, Lin XM, Zhu YJ, Zheng B, Li L, Yang YC, Hou GJ, Chen X, Luo GJ, Huo F, Leng QB, Gonzalez FJ, Jiang XQ, Wang HY, Chen L. Distinct role of nuclear receptor corepressor 1 regulated de novo fatty acids synthesis in liver regeneration and hepatocarcinogenesis in mice. Hepatology 2018;67:1071-1087.

18.Fang T, Lv H, Lv G, Li T, Wang C, Han Q, Yu L, Su B, Guo L, Huang S, Cao D, Tang L, Tang S, Wu M, Yang W, Wang H. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun 2018;9:191.

19.Wang B, Fu J, Yu T, Xu A, Qin W, Yang Z, Chen Y, Wang H. Contradictory effects of mitochondria- and non-mitochondria-targeted antioxidants on hepatocarcinogenesis by altering DNA repair in mice. Hepatology 2018;67:623-635.

20.Li XF, Chen C, Xiang DM, Qu L, Sun W, Lu XY, Zhou TF, Chen SZ, Ning BF, Cheng Z, Xia MY, Shen WF, Yang W, Wen W, Lee TKW, Cong WM, Wang HY, Ding J. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. Hepatology 2017;66:1934-1951.

21.Xiang D, Cheng Z, Liu H, Wang X, Han T, Sun W, Li X, Yang W, Chen C, Xia M, Liu N, Yin S, Jin G, Lee T, Dong L, Hu H, Wang H, Ding J. Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients. Hepatology 2017;65:1566-1580.

22.Wu H, Zhou X, Fu GB, He ZY, Wu HP, You P, Ashton C, Wang X, Wang HY, Yan HX. Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion. Cell Res 2017;27:709-712.

23.Hou G, Chen L, Liu G, Li L, Yang Y, Yan HX, Zhang HL, Tang J, Yang YC, Lin X, Chen X, Luo GJ, Zhu Y, Tang S, Zhang J, Liu H, Gu Q, Zhao LH, Li Y, Liu L, Zhou W, Wang H. Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice. Hepatology 2017;65:1628-1644.

24.Ke S, Chen S, Dong Z, Hong CS, Zhang Q, Tang L, Yang P, Zhai J, Yan H, Shen F, Zhuang Z, Wen W, Wang H. Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations. Hepatology 2017;65:134-151.

25.Lin XM, Hu L, Gu J, Wang RY, Li L, Tang J, Zhang BH, Yan XZ, Zhu YJ, Hu CL, Zhou WP, Li S, Liu JF, Gonzalez FJ, Wu MC, Wang HY, Chen L. Choline Kinase alpha Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression. Gastroenterology 2017;152:1187-1202.

26.Yang C, Tan YX, Yang GZ, Zhang J, Pan YF, Liu C, Fu J, Chen Y, Ding ZW, Dong LW, Wang HY. Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma. J Exp Med 2016;213:859-75.

六、联系方式

E-mail: hywangk@vip.sina.com

电话:021-81875361


上一篇:下一篇: